Fig. 6
LPA1 antagonism reduces microglial proliferation in the ischemic brain at 3 days after tMCAO challenge. Mice were challenged with tMCAO, and AM095 (30 mg/kg, p.o.) was administered immediately after reperfusion. BrdU (50 mg/kg in PBS) was administered twice daily at 12 h interval on days 2 and 3 after tMCAO challenge. Microglial proliferation was assessed at 3 days after tMCAO challenge by double immunofluorescence labeling against BrdU and Iba1. a Representative images of Iba1/BrdU-double immunopositive cells in the marginal zone (area between the periischemic and the ischemic core regions) of the ischemic brain. Scale bar, 50 μm. b Quantification of the number of Iba1/BrdU-double immunopositive cells. n = 5 (sham), 5 (tMCAO+veh), and 4 (tMCAO+AM095). ***p < 0.001 versus sham. ###p < 0.001 versus vehicle-administered tMCAO mice (tMCAO+veh)